LONDON (Reuters) - AstraZeneca Plc's experimental cancerdrug AZD2281 has been given orphan drug status by the EuropeanMedicines Agency for treating women with ovarian cancer,Britain's second biggest drugmaker said on Tuesday.
The drug, which AstraZeneca acquired when it bought KuDOSPharmaceuticals last year, is being developed primarily forbreast cancer. But it has also shown strong evidence of tumorresponse in patients with hereditary ovarian cancer.
Orphan drug designation is given for drugs that treat rarelife-threatening or very serious conditions affecting not morethan five in 10,000 persons in Europe.
(Reporting by Ben Hirschler; Editing by Paul Bolding)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment